• Completed a Drug Master File (“DMF”) process for CBD Active Pharmaceutical Ingredient (“API”) for the US Federal Drug Administration (“FDA”).
• Use of Canadian Drug Establishment Licence (“DEL”) to register API with the FDA for commercial opportunities in pharmaceutical development, novel drugs and generic drugs.
• The cannabis-based drug opportunity is predicted to be over USD$25 billion by 2025⁽ⁱ⁾.
• This is the only US FDA for CBD by a Canadian company and the second natural CBD DMF at commercial scale in all of North America⁽ⁱⁱ⁾.

TORONTO, Feb. 23, 2022 /PRNewswire/ – MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has completed a US FDA DMF for pure natural CBD API. The DMF will enable MediPharm to supply approved API to pharmaceutical companies currently conducting late-stage research. The cannabis-based drug opportunity is predicted to be over USD$25 billion by 2025, and there are over 20 strong novel cannabinoid-based drugs currently in the late-stage research process. These projects will all require pharmaceutical approved API if commercialized. MediPharm has already shipped good manufacturing practice (“GMP”) CBD for development purposes to multiple established pharmaceutical companies.

Management Commentary

Bryan Howcroft, CEO, MediPharm, commented, “The filing of a US DMF further advances MediPharm toward its ultimate objective of becoming a dominant supplier of API to pharmaceutical companies. This is a high value, high margin opportunity, and with the only purpose-built facility in North America to receive a domestic GMP license specifically for the extraction of natural cannabinoids, MediPharm is positioned to capture share in this growing market. In the short to medium term, the DMF unlocks new sales channels and will enable us to further leverage the investments made to date on our high-quality pharmaceutical manufacturing platform. Over the longer-term, it ensures the Company is positioned as the go-to cannabinoid partner for pharmaceutical companies around the world.”

Additional Information

DMFs are regulatory submissions filed with the FDA containing confidential, detailed information about manufacturing, processes, packaging, and stability of APIs to be used in medicinal products for human use. Once the DMF filing is accepted by the FDA, pharmaceutical companies can reference the DMF when making a regulatory submission.

There are many large commercial opportunities for an API in new drug applications (“NDAs”) and abbreviated new drug applications (“ANDAs”). NDAs and ANDAs can be divided into the following four categories:

1. A standalone NDA for new novel drugs.
2. A 505(b)(2) application is a NDA where at least some of the information required for approval comes from studies not conducted by or for the applicant.
3. An ANDA for a previous approved drug creating a new generic drug.
4. A petitioned ANDA is a type of ANDA for a drug product that differs from the novel drug in dosage form, route of administration, strength, or active ingredient.

About MediPharm Labs

Founded in 2015, MediPharm specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, API and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets.

In 2021, MediPharm received a DEL from Health Canada, becoming the only company in North America to hold a domestic GMP License for the extraction of natural cannabinoids. The Company carries out its operations in compliance with all applicable laws in the countries in which it operates.

Cautionary Note Regarding Forward-Looking Information:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, statements regarding: acceptance of the DMF by the FDA and timing thereof; registering API with the FDA for commercial opportunities in pharmaceutical development, novel drugs and generic drugs; predictions regarding the cannabis-based drug opportunity; supplying approved API to pharmaceutical companies currently conducting late-stage research; becoming a dominant supplier of API to pharmaceutical companies; unlocking new sales channels; enabling the Company to further leverage the investments made to date on its high-quality pharmaceutical manufacturing platform; and positioning the Company as the go-to cannabinoid partner for pharmaceutical companies around the world. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm’s filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.

SOURCE MediPharm Labs Corp.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Widely hailed as Cannabis 2.0, the current phase of growth in the legal cannabis market is fueled by cannabis-derived products based on oils, distillates, and isolates. These extracts contain various active ingredients, or cannabinoids, like CBD, THC, and rare cannabinoids such as CBN, CBG and Delta-8 THC. You may have noticed the explosion of CBD products in health food, grocery, and even convenience stores. According to Grandview Research, the global CBD market was valued at $2.8 billion in 2020 and is expected to grow at a 21.2% CAGR over the next several years. It’s a vast opportunity in its infancy, and all of it depends on the extraction and processing of quality base ingredients from the cannabis plant.

Hempsana Inc. recognizes the opportunity and is moving quickly to become a major global player in the world of cannabis derivatives. The company has licenses and approvals in place both in Canada and in the European Union, an EU-GMP compliant extraction, production, and distribution facility, and several contracts already active. Helmed by a diverse and experienced executive team, Hempsana is poised to go public in the very near future and continues to expand its presence across the derivatives market.

Not Just CBD

After decades of effective prohibition on both the consumption of and research into the cannabis plant, the science of cannabis is starting to hit its stride. Over 100 cannabinoids have been identified, going far beyond the widely-known CBD and THC. There are many research studies and clinical trials of the potential benefits of cannabinoids, and scientists have identified a natural system in the human body that interacts with them called the endocannabinoid system. The US Food and Drug Administration went so far as to publish a brief encouraging and supporting cannabinoid research and drug development, a clear sign the science of cannabis has hit the mainstream.

How does all of this research and validation tie into Hempsana and its mission to be the most trusted name in cannabis derivatives? First, researchers and pharmaceutical companies certainly comprise a target market for Hempsana’s cannabinoid derivatives. They need something pure and clean to study, and Hempsana can provide. Second, the scientific momentum is fueling acceptance of the plant as a viable alternative to some more traditional products, widening Hempsana’s playing field. Perhaps most importantly, research has uncovered over 100 cannabinoids, each one with the potential to benefit people. Each of these compounds requires extraction and purification, giving Hempsana market opportunities far beyond the common CBD and THC array of products.

Click here to receive an investor presentation and corporate updates

To be clear, Hempsana is not ignoring CBD and THC but rather sees an opportunity to be an early mover with cannabinoids such as CBN and Delta-8 THC. In Hempsana’s native Canada, there are currently a couple of major players in the cannabis extraction world. Both MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) and The Valens Company (TSX: VLNS) (OTCQX: VLNCF) are mostly focused on THC and CBD extracts, and rightfully so. Hempsana firmly believes two things. One, the market growth and potential for the global THC and CBD products is very large and allows room for competitors. Two, there is tremendous value in developing lesser-known cannabinoid products.

Hempsana’s Story

Hempsana was founded in October 2018 in Toronto. The company received confirmation to extract CBD oil from industrial hemp in Hungary, EU in February 2019. This was quickly followed by a Health Canada Industrial Hemp License in August 2019, and the Health Canada Standard Processing License in May 2020 for its Canadian operations. Hempsana’s wholly owned 8,000 square foot EU GMP compliant facility located in Goderich, Canada, was fully completed and commissioned in Q4 2020, with commercial production launched in December 2020.

The Hungarian component is a key to future growth, providing entry into the lucrative EU market. The Canadian EU-GMP compliant facility was also built with international export capabilities in mind, as those requirements are generally considered the most stringent in the world. From a facility standpoint, the table was set in the first two years of Hempsana’s existence.

Since its inception, the company has executed a number of processing and offtake agreements, with current production of cannabinoid derivatives set for over 27,000 kg of biomass extraction.  Hempsana offers three basic types of ingredients: crude full-spectrum oil, full-spectrum high concentrate distillate, and active pharmaceutical ingredient (API) grade isolate. These ingredients form the foundation of products ranging from topical creams, to foods, to pharmaceutical drug candidates.

Hempsana sells ingredients wholesale to qualified buyers that formulate and manufacture their own products. The company also offers more comprehensive services that manage refinement, and include purification, remediation, and even formulation services to cannabis companies without those capabilities. Hempsana also offers white label services, partnering with clients to take products from the idea stage all the way to a ready-to-sell package.

What’s Next

Consider this all an introduction to a new player in the global cannabinoid derivatives market. Hempsana recently announced a business combination agreement that sets the stage for its near-term go-public event, which will introduce the company to new funding sources to help fuel its growth plans. Hempsana is currently in the process of partnering with national brands in Canada, EU, and Asia to create sales verticals in key growth areas including the health supplement, topical cream, vape, and edibles markets. It’s an exciting time for the people at Hempsana, and interested investors are encouraged to keep an eye on this space for further developments.

Click here to receive an investor presentation and corporate updates

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Robin Lefferts

Cannabis extracts are poised to become a $28.5 billion market by 2027, according to Grand View Market Research, representing a 16.6% compound annual growth rate. At the same time, the functional mushroom market is forecast to reach $34.3 billion by 2024, which represents a respectable 8% compound annual growth rate.

Let’s take a look at the growing demand for cannabis and other extracts and why Pure Extracts Technologies Corp. (CSE: PULL) is well positioned to capitalize on the market.

Powering Next-Gen Products

Canada legalized cannabis extracts in October 2019, opening the door to edibles, beverages, topicals and vaping products. While dried cannabis still represents about 70% of sales, cannabis extracts and edibles have each captured about 14% of the market. Cannabis edibles, in particular, have become one of the fastest growing segments of the market.

Growth in Cannabis Edibles – Source: Canada Government

There’s no doubt that cannabis extracts, such as edibles and beverages, appeal to a wider consumer market than dried cannabis. On the other hand, the production of hash, rosin and other extract-based products has provided legal alternatives to popular black-market products – where much of sales remain outside of legal dispensaries.

Many large, licensed producers have begun scaling up their in-house extraction capabilities, but many others have outsourced extraction to specialists. With experienced teams and equipment, these companies offer better economies of scale by taking in raw cannabis and converting it into a variety of extract-based products for resale to consumers.

Recurring Revenue & Blue-Sky Potential

Pure Extracts Technologies Corp. (CSE: PULL) provides tolling and white-labeling services via its state-of-the-art 10,000 sq. ft. EU GMP-compliant cannabis and hemp extraction facility. After securing a processing license and agreements with Licensed Producers, the Company is already generating revenue through tolling agreements and will soon scale up its white label business.

Click here to receive and investor presentation and corporate updates

In addition, the Company has developed its own nationally recognized vape pen brand, called Pure Pulls, with over 34 proprietary formulations. The team is in the process of applying for a sales license to bring Pure Pulls back to market in the near-term, along with its edibles brand, Pure Chews, which could open the door to blue sky revenue potential.

The Company is also expanding its business to include mushroom extracts by working on functional mushroom extraction processes compatible with its existing infrastructure. Management believes that there exists a significant opportunity for it to become an important extraction partner for the commercialization of new functional mushroom products.

Exceptional Management Team

Pure Extracts Technologies (CSE: PULL) has assembled an impressive management team and advisory board. With a flat management structure, the team is laser-focused on creating high-quality products and building a sustainable business that’s EBITDA positive. These efforts could unlock significant long-term shareholder value in a growing market.

 CEO Ben Nikolaevsky joined the Company after serving as President and CEO of Natura Naturals Inc., a private Licensed Producer that was sold to Tilray Inc. (NASDAQ: TLRY). Founder and COO Doug Benville brings substantial experience with cannabis extracts, while Andy Gauvin brings a wealth of sales experience after serving as a vice president at Moosehead Breweries.

In addition to its management team, the Company recently appointed Dwight Duncan, a senior member of the Ontario Legislature, to its Board of Directors, as well as Dr. Alexander MacGregar, an expert in drug delivery technologies, to its Advisory Board. These appointments reflect its focus on regulatory compliance and research and development.

Click here to receive and investor presentation and corporate updates

The Bottom Line

Pure Extracts Technologies Inc. (CSE: PULL) recently secured a processing license from Health Canada and went public on the Canadian Securities Exchange. With an experienced and focused team at the helm, investors may want to take a look at the stock as a way to capitalize on the growing demand for cannabis and other plant-based extracts.

For more information, visit the Company’s website or download their investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Most people think of white buttons at the grocery store when they think of mushrooms, but in reality, there are hundreds of different kinds of mushrooms. Functional mushrooms—like functional foods and beverages—are mushroom varieties that provide a health benefit, ranging from run-of-the-mill vitamins and minerals to important nutrients, including selenium, potassium, riboflavin, niacin, proteins, and fiber.

As with cannabis and other plant-based medicines, the beneficial properties of functional mushrooms can be extracted into a wide range of formats. These formats provide patients and consumers with different product options, improved bioavailability and greater consistency, which opens the door to a range of medical and consumer use possibilities.

Let’s take a closer look at functional mushrooms, how extraction plays a role in product development and how Pure Extracts Inc. (CSE: PULL) (listing pending) plans to capitalize on the space.

Functional mushrooms provide a wide range of potential health benefits that researchers are only starting to understand. While some have become popular superfoods, others are an important source of vitamins for supplements.

Some popular functional mushrooms include:

• Reishi:  a Traditional Chinese Medicine ingredient that supports restful and healthy sleep, reduces stress and boosts the immune system.
• Chaga: rich in antioxidants that could help strengthen the immune system—it was even used as a coffee ration in World War II.
• Shiitake: a widely known superfood with nine amino acids and a diverse range of important vitamins and minerals.
• Oyster mushrooms: contain beta-glucans that could improve cholesterol and blood sugar markers, as well as boost the immune system.
• Trumella: a common source for plant-based vitamin D as it contains more of the vitamin than any other known food source.

Psilocybin has become one of the most popular mushrooms following the movement to legalize psychedelics across several states and some countries. Over the past couple of years, researchers found that the mushroom’s psychedelic properties could have wide ranging implications across psychology and psychiatry practices targeting mental illnesses.

Click here to learn more about investing in mushroom extraction technology

Many of the world’s most popular medicines originated from plants—specifically, plants in the Amazon rainforests. Of course, modern medicine doesn’t typically involve consuming or smoking exotic plants—with the exception of medicinal cannabis use. The beneficial properties are extracted into safe and consistent formats that physicians can prescribe.

Vitalis Extraction Technology – Source: Vitaliset

The same is true for over-the-counter supplements that extract beneficial properties from plants and other sources and combine them into a more palatable format. While supplements aren’t subject to as much regulation, extraction can help them meet FDA guidelines for safe production and an improved shelf life compared to the original formats.

There are many different extraction methods used depending on the plant or input source, but CO2 extraction has become one of the most effective modern methods. When pressure is applied to CO2, the gas turns into a liquid that can be used as a very inert, safe, liquid solvent to extract oils from plant biomass, such as mushrooms, hemp and cannabis.

Click here to learn more about investing in mushroom extraction technology

Functional mushrooms are experiencing a renaissance fueled by interest in psilocybin for the treatment of mental health disorders. While there are a growing number of cultivators, investors may want to take a closer look at the extractors that are focused on functional mushrooms as potential opportunities given their innovative business models.

Pure Extract Technologies Inc. – which plans on going public on the Canadian Securities Exchange (CSE) in Q3 of this year using the symbol “PULL” – has built an EU-GMP compliant extraction facility in British Columbia with an initial focus on extracting cannabis and long-term plans to extract mushrooms. Extracts in both categories are expected to see tremendous growth over the coming years.

The business model is compelling for investors. After signing agreements with Licensed Producers, the Company either charges a toll for extraction services or produces white-label products on behalf of other companies, creating very little overhead and predictable, recurring revenue with attractive margins.

While the Company’s initial business will come from tolling and white labeling, Pure Extracts anticipates creating in-house brands that will benefit from the ready supply of biomass from Licensed Producers and its in-house extraction (i.e., at a lower cost). These dynamics could create an attractive business line in the future.

Functional mushrooms are quickly becoming a preferred health food and potential source of treatment options for mental health disorders. While there are a growing number of companies focused in the space, investors may want to take a look at extraction providers, such as Pure Extract Technologies Inc. (CSE: PULL), given its strong business model and unique focus.

For more information, visit the company’s website or download their investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

There are only a few times that investors get an opportunity to get in front of an emerging industry. Think about cannabis or electric vehicles in recent times. There can be tremendous upside, but there is generally a steep learning curve because the markets are so nascent and unique that everything is a guessing game about the best business strategies.

One of the latest emerging trends is centered on mushrooms. Here, investors get to enjoy shortening the learning curve because of the similarities between psychedelics and cannabis. Simply, the cannabis industry did most of the heavy lifting with swaying the thinking of lawmakers and lifting negative stigmas attached to once-illicit drugs with respect to bona fide value to fill gaping holes in medicine where traditional drugs have failed miserably. 

It also taught investors, from self-directed to institutions, where real value can be found. Fact is that most companies lurched into the marijuana space trumpeting massive cultivation facilities and plans to keep expanding. Greenhouse space was king. Like most kings, it had an expensive lifestyle, leaving those leading growers with huge cash burns and net losses.

A better plan was to seek out businesses integral to the industry with better capex and operating models. As often happens, technology and innovation were the answer, pointing squarely at extractors. These companies don’t assume the risk of growing the plant, but if properly integrated, can control the rest of the supply chain to deliver an ingredient or a finished consumer product.

Click here to learn more about investing in mushroom extraction technology 

Legal Mushrooms: A Two-Prong Play

Forget about so-called “magic” mushrooms, those that contain psilocybin and psilocin, the psychedelic components responsible for the “trip” when ingested. Functional mushrooms – those that are free of psilocybin and psilocin – represent a growing market themselves. 

In fact, the functional mushroom market is one of the fastest growing segments in consumer packaged goods.

These mushrooms, which have names like Lions Mane, Turkey Tail, Shiitake, Reishi, Cordyceps and Chaga, offer a multitude of known benefits pertaining to health, sleep, beauty and more. To that point, the global medicinal mushroom market is expected to reach $13.88 billion by 2024, as the trend accelerates, according to a presentation by Pure Extract Technologies Inc. (Pure Extracts) CSE: PULL (listing pending), a privately-owned plant-based extraction company expanding its capabilities to include mushrooms. 

 “Even though people have been utilizing the therapeutic benefits of mushrooms for centuries, it is really only now starting to become a trend that Main Street and Wall Street are recognizing,” commented Doug Benville, founder and COO of Pure Extracts, in a phone conversation with Cannabis FN. “We’re leveraging our experience in carbon dioxide and ethanol extraction for full spectrum cannabis products to take a leadership position in mushrooms, first with functional and then psychedelic.”

The Company is starting with tincture and soft gel products from functional mushroom extracts, with plans to move into beverages and nasal sprays during Q4 this year and psychedelics early in 2021.

Click here to learn more about investing in mushroom extraction technology

Benville is joined by some household names betting psychedelics are the next frontier in medicine. Last year, Shark Tank billionaire Kevin O’Leary and Canopy Growth co-founder Bruce Linton teamed up as investors in Toronto-based startup Mind Med.

While psilocybin remains illegal at the national level in the U.S. and Canada, it can be researched under special licenses. To that end, there is a growing body of clinical evidence supporting anecdotal references that psychedelics can provide relief for hard-to-treat diseases and conditions like PTSD, bi-polar, drug and alcohol dependence, obesity, narcolepsy, OCD, Alzheimer’s and ADHD. 

With the help of $17 million in donations, Johns Hopkins in September opened its new center for psychedelic research. 

Also suggesting growing acceptance and recognition of psilocybin, in March 2019, the FDA approved the nasal spray Spravato (esketamine) in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried other antidepressant medicines but have not benefited from them (treatment-resistant depression). Despite a restricted distribution system owing to risks of misuse, sales of Spravato are forecast to reach $1.3 billion annually by 2024.

Out in Front & De-Risked 

Headquartered just north of Whistler in Pemberton, British Columbia, Canada, Pure Extracts has a distinct advantage over any potential competition with its 10,000 square-foot purpose-built facility and bulletproof methodology learned through years of cannabinoid extract production. Development is underway to expand the facility to 25,000 square feet, including dedicated lab and packaging spaces.

Pure Extracts is re-defining mushroom extraction. “We’re not just going to produce simple extracts like some companies already do for functional mushrooms. We’re fully integrated, scalable and using modern technologies to effectively and efficiently produce non-psychotropic nutraceuticals and next-generation functional mushroom products,” said Benville.

To that end, the Company has inked an advisory agreement with Dr. Alexander MacGregor, founder of the Toronto Institute of Pharmaceutical Technology (TIPT).

Management believes that overcoming the industry hurdle of exorbitant costs for psilocybin will make them the go-to manufacturer as studies pick-up on psychedelics. Currently, prices for a gram can be as high as $10,000, a price point that Pure Extracts expects to cut significantly while maintaining high margins.

Planning to conduct business worldwide, the Company’s facility is built to European Union Good Manufacturing Practices (EU GMP). Domestically, management is presently awaiting approval of a Standard Processing License from Health Canada, which will have a cascade effect with orders already on the books.

Notably, expansion into mushrooms is de-risked by these current cannabis and hemp agreements, including tolling agreements signed for 120,000 kilograms of annual capacity. Pure Extracts also has an exclusive Canadian and international license signed to produce a cannabis-based gummy for an unnamed “large U.S. alcohol brand”.

Simultaneously, the Company is prepping to re-launch its Pure Pulls rechargeable cannabis vape pens in the second half of this year.

While companies jump on the psychedelic bandwagon, Pure Extracts stands out by being a first mover in the extraction space. Regardless which avenue a company goes down with mushrooms, they are going to need extraction services at the minimum. With the growing popularity of mushrooms, the Company seems to be timing its IPO – planned for the coming months – absolutely perfectly.

Click here to learn more about investing in mushroom extraction technology

Pure Extracts Company Contact:

Aaron Wong

Business Development

[email protected]

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Centene. Energy Transfer. Tech Data. Arrow Electronics. What do these companies have in common? They each generate over $40 billion a year in revenue and most people have never heard of any of them. Investors that have enjoyed triple-digit returns from all of them over the last decade probably don’t mind too much that the names are relatively obscure.

GreenStar Biosciences Corp.(CSE: GSTR) (OTC: GTSIF) is making its mark in the cannabis industry and doing so through partnerships that don’t put its name in lights, but they certainly put value in the company. The tech and services company is a provider of real estate, financial, management, IP and branding support to licensed U.S. cannabis businesses. In these efforts, GreenStar partners and makes investments in innovative or disruptive technologies and businesses.

Tenant Partner: Cowlitz

GreenStar is steeped with experience in the cannabis industry earned while refining strategies in Washington, the first state (along with Colorado) to legalize recreational marijuana in 2012. With that experience in tow, the Vancouver-based company – through its subsidiary – has a variety of agreements with Cowlitz County Cannabis Cultivation, Inc., one of the largest cannabis companies in Washington. GreenStar refers to companies in its portfolio of operations as “tenant partners.” 

Cowlitz is a Tier 2 processor, meaning it utilizes mid-size canopies ranging from 2,000-10,000 square feet, while maintaining a community-minded business model. The company is also one of the largest independent buyers of dried flower in Washington. It needs to be because it produces about 2 million cannabis pre-rolls each year. 

Click Here to watch Cowlitz County Cannabis Grow’s ~ Water’s from the beginnings of time ~ On-Site Video 

Across the brands owned by GreenStar: Dab Dudes, Hi Guys and Cowlitz Gold, Cowlitz has built a reputation for premium cannabis at fair prices, with products on shelves in about 20% of all the cannabis retailers across Washington.

Cowlitz is a growth story in the expanding Washington market that recorded sales of $1.49 billion in 2017 and forecasted to rise to $2.6 billion by next year.

Throughout the first seven months of 2019, data from the Washington State Liquor and Cannabis Board showed Cowlitz generated $11.8 million in sales. 

Click here to receive an Investor Presentation & Corporate Updates

“Cowlitz’s strong continued sales in a highly competitive market is positive and provides the perfect base for GreenStar’s plans to expand its footprint across the United States with similar best-in-class companies,” commented GreenStar CEO Rahim Rajwani in a news release in October. Rajwani was referencing the company’s plans to penetrate other legal markets, with Michigan, a top medical marijuana state that legalized recreational marijuana last year, a top priority.

GreenStar + Progressive Herbs = Capri

Earlier this year, GreenStar made a savvy business move in partnering with Progressive Herbs, forging a joint venture under the name Capri PHGS LLC. The partnership brought Progressive Herb’s proprietary cultivation technology into GreenStar’s portfolio, which it promptly took to Cowlitz’s facilities to grow plants for independent lab testing.

2,500 cannabis plants were grown using the patent-pending nutrient system, then analyzed at Praxis Laboratory, an accredited Washington State testing facility. The results were nothing shy of spectacular, including higher-than-normal cannabinoid levels (22.85% to 32.54%) grown at lower operational costs. Praxis and accredited heavy-metal screening lab Medicine Creek Analytics testing further verified that the plants were free of pesticides, herbicides, fungicides, heavy metals and other contaminants. 

In addition to shaving grow costs, the initial test plants grew faster than conventional methods. All plants were harvested in roughly 72 days, meaning that five harvest cycles can be completed in one year. 

The next phase of testing will be designed to validate the scalability of the new technology. The plan is not only for Capri to use the technology itself to produce high-quality cannabis at lower costs, but to license the technology to third parties as a separate revenue stream.

Click here to receive an Investor Presentation & Corporate Updates

Oral Cannabis Strips

Down the road, it will be interesting to see how this technology squares with GreenStar’s partnership with PharmaStrip to produce cannabis-infused mouth strips. This is an under-appreciated method for reliably delivering precise amounts of cannabinoids with rapid uptake. GreenStar doesn’t speak a lot on this part of the business as it devotes resources to Cowlitz and Capri, but the company is quietly positioned to emerge as a leader in the space whenever it flicks the switch.

Perhaps one day, GreenStar will be a household name with partnerships with Cowlitz, Capri, PharmaStrip and whatever else it acquires in the future under its umbrella. Maybe it will forever be the obscure like the goliaths mentioned above. For now, though, the company seems perfectly content with business development, not touting its own name, as its highest priority, but now you know.

Click here to receive an Investor Presentation & Corporate Updates

For Additional Information on GreenStar Biosciences Corp please click here to visit the website

Click Here to Receive CFN Media’s Newsletter Every Week in Your Inbox

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ash Stringer

In the burgeoning cannabis industry, testing companies are often considered the gatekeepers to success. Between consumer demand and regulatory obligations, marijuana producers are compelled to provide a full analysis of what they’re putting on the market and accurate results are crucial. FluroTech (TSX-V: TEST) (OTCQB: FLURF) is a Canadian-based provider of cannabis and hemp testing technology that at its core is dedicated to offering solutions designed to increase safety, awareness, and education. Their patented CompleteTest system utilizes advanced fluorescence spectroscopy technology to provide results in minutes for manufacturers right at their facilities.

Danny Dalla-Longa, President and CEO of FluroTech

CFN Media spoke with FluroTech President and CEO Danny Dalla-Longa at the recent MJ Micro conference in Beverly Hills to learn more about some big news recently announced and how the firm’s technology could possibly prevent the next VapeGate.

CFN:  You were recently awarded a research license in Canada. What does this mean for the company?

Danny Dalla-Longa:  It allows us to acquire and freely test commercial amounts of cannabis and hemp. It was a bigger problem in the hemp market since existing regulations do not allow for the purchase of hemp for testing. We had to go to the hemp growers’ facilities to conduct tests. The University of Lethbridge, for example, is developing 40 different strains of hemp and they have them all analyzed, so that allows us to obtain samples from them to develop our analytical testing protocols.

Click here to receive corporate updates on FluroTech

The license also allows us to accelerate our efforts for a GMP certification application which is planned for submission by the end of Q1, 2020.  

CFN:  How could firms like FluroTech help prevent issues such as the so-called vape crisis happening right now in America?

DD:   Our biotracking technology, which introduces an approved biomarker into the plant, tracks the plant through the entire process enabling the end-product to be analyzed with our CompleTest device to determine whether it’s legal or illicit, and which LP legally produced it.  We expect that to be a major breakthrough. It’s the same concept as seed to sale, but instead of tracking a package, we’re tracking the plant right through to the end consumer.

We expect regulators won’t require much convincing as to the positives of biotracking. If you grow cannabis or hemp, there’s a need to identify the origin, which may help suppress the black market which can only enhance safety and tax revenue. 

CFN:  What does the company have on deck for 2020?

DD:  Well, we’re looking forward to penetrating the U.S. market, and further adoption in the Canadian market. In Canada, with approximately 200 licensed producers of cannabis and hemp, we plan to cover the market in the next 12 to 18 months. In the US, we’re in discussions with potential joint venture (“JV”) partners to effectively distribute our technology.

Additional offerings are also in development. We do have a cadmium test, which will be commercially available within about a month.  Further development of the remaining heavy metals test for Lead, Mercury and Arsenic are next, followed by pesticides and mold. FluroTech is open for further JV discussions to accelerate our development pipeline.

CFN:  What else should the readers know about FluroTech?

DD:  We currently remain focused on the hemp market especially in the US, our patented biotracking technology and development of further testing protocols which will enhance revenue.  Our first sales were just realized near the end of our Q3 in September and anticipate sustained quarterly revenue growth. 

We’re also fielding inquiries from companies based in other countries so I can see discussions in the near future regarding sales and JV’s in other parts of the world where cannabis and hemp are legal.

Click here to receive corporate updates on FluroTech

To learn more about FluroTech click here to visit the website

Click Here to Receive CFN Media’s Newsletter Every Week in Your Inbox

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com  (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Rachelle Gordon

Rachelle Gordon is a Minneapolis-based writer. Find her online at www.rachellegordon.net.

• Joel Toguri joins as Senior Vice President of Commercial
• Supreme Cannabis strengthens senior team with the addition of experienced sales executive
• Toguri brings over 20 years of regulated industry expertise to Supreme Cannabis

TORONTO, November 4, 2019 – The Supreme Cannabis Company, Inc. (“Supreme Cannabis” or the “Company”) (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) announced today that Joel Toguri has joined the company as Senior Vice President (“SVP”) of Commercial. In this role, Mr. Toguri will establish and oversee the Company’s provincial and retail sales strategy across all brands.

“Mr. Toguri’s impressive career spans the cannabis, beverage alcohol and apparel industries. He brings over 20 years of regulated industry knowledge and pertinent cannabis distribution expertise to Supreme Cannabis. It is a privilege to welcome a proven and skilled leader to our continuously improving team,” said Navdeep Dhaliwal, CEO of Supreme Cannabis. “From the outset, Mr. Toguri will lead the launch of Blissco’s high-quality CBD oils to the Canadian wellness market and continue to build the 7ACRES brand and distribution to cement it as the leading premium flower brand nationally. The Company’s talented sales team will benefit from Joel’s proven leadership abilities and strong industry network across Canada. As we grow our team, we believe our focused business and industry leading culture will continue to attract exceptional personnel like Mr. Toguri.”

As Supreme Cannabis SVP of Commercial, Mr. Toguri will develop and drive forward leading sales strategies, business development and retail growth opportunities.  Prior to joining Supreme Cannabis, Mr. Toguri led sales for a large Ontario-based licensed producer in Canada, managing medical and recreational sales to patients and consumers. Before entering the cannabis industry, Mr. Toguri served as Vice President of Sales and Operations at Southern Glazer’s of Canada. Mr. Toguri was responsible for establishing the company’s footprint across Canada and leading a national sales team of more than 90 people. In three years under his direction, the company became one of the leading wine and spirits agents and brokers in Canada. Prior to Southern Glazer’s, Mr. Toguri held leadership roles at MolsonCoors and Beam Global Spirits & Wine.

About Supreme Cannabis.

The Supreme Cannabis Company, Inc. is a global diversified portfolio of distinct cannabis companies, products and brands. Since 2014, the Company has emerged as one of the world’s fastest-growing, premium plant driven-lifestyle companies by effectively deploying capital, with an emphasis on disciplined growth and high-quality products.

Supreme Cannabis’ portfolio includes 7ACRES, its wholly-owned subsidiary and multi-award-winning brand; Blissco, a wellness cannabis brand and a multi-licensed processor and distributor based in British Columbia; Truverra Inc., a global medicinal cannabis brand and licensed cultivator; Cambium Plant Sciences, a plant genetics and cultivation IP company; Medigrow Lesotho, an cannabis oil producer located in southern Africa; Supreme Heights, an investment platform focused on CBD brands in the UK and Europe and a brand partnership and licensing deal with Khalifa Kush Enterprises Canada.

Supreme trades as FIRE on the Toronto Stock Exchange (TSX: FIRE), SPRWF on the OTC Exchange in the United States (OTCQX: SPRWF) and 53S1 on the Frankfurt Stock Exchange (FRA: 53S1). Follow us on Instagram, Twitter, Facebook and YouTube.

We simply grow better.

Forward-Looking Information

Certain statements made in this press release may constitute forward-looking information under applicable securities laws. These statements may relate to anticipated events or results including the Company’s next phase of growth, the closing of the acquisition of Truverra and the role of Chief Advocacy Officer & Managing Director, Flower and Concentrates and other statements that are not historical facts. Particularly, information regarding our expectations of future results, targets, performance achievements, prospects or opportunities is forward-looking information. Often, but not always, forward-looking statements can be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “believe”, “estimate”, “plan”, “could”, “should”, “would”, “outlook”, “forecast”, “anticipate”, “foresee”, “continue” or the negative of these terms or variations of them or similar terminology. Forward-looking statements are current as of the date they are made and are based on applicable estimates and assumptions made by us at the relevant time in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. However, we do not undertake to update any such forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable securities laws in Canada. There can be no assurance that such estimates and assumptions will prove to be correct.

Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements as discussed in the “Risk Factors” section of the Company’s Annual Information Form dated October 2, 2018 (“AIF”). A copy of the AIF and the Company’s other publicly filed documents can be accessed under the Company’s profile on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com. The Company cautions that the list of risk factors and uncertainties described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information.

SOURCE The Supreme Cannabis Company, Inc.

More Information.

Madelin Daviau, Investor Relations
Email: [email protected]
Phone: 416-466-6265
supreme.ca

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ash Stringer

RYAH Finds Top Priority is Treating Mental Health, Over 28,000 Women Surveyed

New York, NY, October 30, 2019 – RYAH Medtech, Inc. (“RYAH” or the “Company”), a big data and technology company focused on valuable predictive analysis in the global medical plant intake industry, has released a data analytics report on women and their medical use of cannabis. Surveying feedback from 28,211 women, the report found that the average female patient prefers strains that are high in CBD, THC, and well-balanced strains to help treat mental health conditions.

“The female patient demographic has not received enough industry attention or study up to this point. Making up more than 45% of the patient pool, it’s our responsibility to better understand what this demographic looks like, which medical issues they are seeking treatment for and what treatments are providing successful outcomes. Women are turning to medical cannabis to treat their mental health concerns and it’s a valuable insight for care providers that we have learned strains high in CBD are helping them gain relief,” said Gregory Wagner, Chief Executive Officer of RYAH.

The data, taken from RYAH’s propriety data pool, and related insights, examine female medical cannabis patient demographics and how women utilize different strains of medical cannabis. The report found that women are a growing segment of the medical cannabis market, comprising 45.1% of the patient population currently using RYAH’s Data Platform. The average female patient prefers strains that are high in CBD, THC and well-balanced strains. They also prefer Indica and Sativa strains equally. Mirroring the common ailments most treated by men, women are seeking medical cannabis for anxiety, depression, stress and pain relief.

In comparing the current data with data in two other reports on women and cannabis, RYAH’s data mirrored and confirmed that women are more likely than men to use cannabis for the specific treatment of fibromyalgia, nausea, anorexia, irritable bowel syndrome and migraines. These reports also indicated that women started to use medical cannabis later in life than men, typically after 30 years of age.

The report also went into some of the specific strains that women prefer for their treatment. Women prefer Cannatonic (7-15% THC, 12% CBD Indica-dominant), Harlequin, Super Lemon Haze (>22% THC, <1% CBD, Sativa-dominant), and Purple Candy for the treatment of anxiety. They preferred AD/CA (>1% THC, 20% CBD, Indica-dominant), Gorilla Glue, Harlequin, and Purple Candy for the treatment of fibromyalgia.

“Medical cannabis has the ability to change lives for the better and we are hopeful the insights from our data pool and related analysis can improve patient outcomes and inspire further study,” added Wagner.

The full report and related insights are available online at: https://us.ryah.com/wp-content/uploads/2019/10/RYAH-OCTOBER-REPORT-.pdf

About RYAH Medtech, Inc.
RYAH is a big data and technology company focused on valuable predictive analysis in the global medical plant intake industry. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant medical data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is also relevant for growers, dispensaries and Licensed Processors (LPs) to monitor and manage plant strain effects on patients. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete medical plant lifecycle, from seed to consumption.

Forward-Looking Statements
Certain statements contained in this press release constitute “forward-looking information” as such term is defined in applicable Canadian securities legislation and United States rules and regulation. The words “may”, “would”, “could”, “should”, “potential”, “will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions as they relate to the Company; execution of additional distribution agreements; and the results users may receive from using RYAH are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business and economic conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, including the successful completion of acquisitions, business retention, and strategic plans and to attract, develop and retain key executives; difficulty integrating newly acquired businesses; the ability to implement business strategies and pursue business opportunities; disruptions in or attacks (including cyber-attacks) on the Company’s information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current laws and regulations; a novel business model; granting of permits and licenses in a highly regulated business; the overall difficult litigation environment, including in the United States; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the occurrence of natural and unnatural catastrophic events and claims resulting from such events; and the risk associated with a business in the cannabis industry. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Thursday, October 17, 2019 marked a milestone moment for the world of legal recreational cannabis with new product forms like concentrates, extracts, vaporizers and edibles becoming legal in Canada. This second phase of legalization comes only one-year after Canada’s federal legalization of recreational adult-use cannabis. 

In the inaugural episode of a new cannabis podcast called “Session Garden” hosted by John Fowler, Chief Advocacy Officer at The Supreme Cannabis Company (TSX: FIRE) (OTCQX: SPRWF), an esteemed panel tackles the opportunities and obstacles associated with Cannabis 2.0, the colloquial name given to the new Canadian cannabis regulations that just came into effect on October 17th. 

John Fowler Chief Advocacy Officer of The Supreme Cannabis Company

John Fowler is a well-recognized name in the cannabis industry, serving as an advocate, activist and entrepreneur, including founding Supreme Cannabis. Supreme Cannabis is a TSX (FIRE) and OTCQX (SPRWF) listed company, it is the holding company for a leading diversified portfolio of premium cannabis brands, products and facilities. Now, the company and John launch Session Garden to address, as John puts is, “a lack of hard-hitting and insightful content focused on all aspects of the cannabis community.”.

Click here to receive an investor deck and corporate updates

In the first episode, Fowler sits down with Brigitte Simons, Chief Scientific Officer at Pasha Brands, Brad Poulos, a professor of cannabis entrepreneurship at Ryerson University, and Talaal Rshaidat, Chief Scientific Officer at humble+fume, to take a deep dive into the direction of the cannabis market, challenges facing the industry and who will be winners with Cannabis 2.0.

Cumulatively, the panel has a highly relevant and diversified background in cannabis, ranging from technology to brand and product development.

The 2.0 Groundwork

When Canadian legislatures legalized adult-use cannabis on October 17, 2018, they didn’t have any true references to use for guidelines. As such, they didn’t jump in with both feet by any stretch of the imagination, only permitting the sale of cannabis flower and oil. Cannabis 2.0 will introduce new products and market segments, including concentrates (which serve as the basis for vape pens), topicals and ingestible products, such as drinks and edibles. As noted by Ms. Simons, there will also be an insurgence of other items, such as bath and luxury beauty care and wellness products.

Pasha is eager to re-innovate baked goods and specialty products, such as those catering to healthier lifestyles, including plant-based products that will eliminate usage of preservatives and high fructose corn syrup.

Shy of some Health Canada restrictions on edible products, Rshaidat describes the opportunity to introduce new products as “free reign.”

“The consumer is waiting,” said Simons. “They’ve proved to us before in those type of sales that the consumer is ready for that,” she added.

 Click the photo above to listen to Supreme Cannabis’ John Fowler’s Podcast “Session Garden”

Cannabis 2.0 Shakes Up Everything…Are You Ready?

Deloitte estimates that the new products coming to market in Canada will add another $3.0 billion to the industry size on top of sales of flowers and oils. So what will be the dominant market segment? 

On this point, the panel sparks up a conversation on how different types of cannabis consumers will likely lean towards different product forms. The panel digs deeper into the topic of 2.0 products, touching on the impact of simply adding cannabinoids to existing products versus innovating new ones.

Click here to receive an investor deck and corporate updates

The panel agrees that innovation and thoughtfulness in product development are going to be integral to the success of 2.0 products. For example, while the emphasis right now is largely on the popular cannabinoids CBD and THC, the panel discusses the opportunities ahead with innovation that will recognize and tap into the more than 100 other known cannabinoids. When contemplating about the market and where it can go, this sort of thinking speaks plainly to how early we still are in product development and the significant potential that lies ahead.  

Educating the Public

On the podcast, the group discusses one of the greatest challenges to manufacturers, with limited tools to reach consumers, it is difficult to educate consumers on the full arc of cannabis consumption. Science plays a tremendous role in the user experience and that can be difficult to convey. Things such as pharmacokinetics and bioavailability can vary greatly between strains and product forms. When advertising is negligible and communications are restricted, how can companies educate consumers? Fowler and his guests dive deep into this topic and discuss the varying information needs of different consumers, explaining why education is more important now than ever.

Click here to receive an investor deck and corporate updates

So Who Wins?

Simply, companies that have the foresight and solutions to overcome the aforementioned challenges detailed by Fowler, Simons, Poulos and Rshaidat. An overarching takeaway is that there are tremendous growth opportunities for ancillary companies to fill gaps in the value chain.

There is also something to be said about being forward-thinking towards Cannabis 3.0. All the panelists are in the position they are because they made prescient decisions to be prepared for Cannabis 2.0 and now they’re looking for what’s next. 

Insightful and entertaining, but most importantly, informative, John Fowler’s Session Garden should become required listening for all in the cannabis space. We are already looking forward to episode two, set to air this Thursday October 31st. 

Click here to receive an investor deck and corporate updates

 For additional information, visit the company’s website at: https://www.supreme.ca/about-supreme-cannabis

Click Here to Receive CFN Media’s Newsletter Every Week in Your Inbox

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com(the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ash Stringer